Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Telomir seeks FDA approval for Telomir-1 to treat breast cancer
The safety studies reported no toxicities, favourable safety profiles, consistent systemic exposure, and predictable pharmacokinetics. Credit: Sai Thaw Kyar / Shutterstock.com.
The safety studies reported no toxicities, favourable safety profiles, consistent systemic exposure, and predictable pharmacokinetics. Credit: Sai Thaw Kyar / Shutterstock.com.